Branford, S., Albeer, A., Ramiro, Ă. V., McConnell, J., Abáigar, M., Rinke, J., Polakova, K. M., Mayer, J., Stuckey, R., Yassin, M., Shih, L., Alhuraiji, A., Gambacorti-Passerini, C., Kim, D., Ong, S. T., Stoklosa, T., Krizkova, J., Laznicka, A., Jeziskova, I., Casares, M. T. G., Akiki, S., Hasaneen, M., Colombo, F., Chuah, C., PÄ™pek, M., RodrĂ­guez, Ă., GarcĂ­a, A., Pfirrmann, M., Evans, N., Hochhaus, A., Hughes, T., Kok, C. H., Ernst, T. (2025). Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform. Blood. https://doi.org/10.1182/blood-2025-75